IM-1021

Phase 1Biologic

IImmunome, Inc.

IM-1021 is one of 5 biologic programs targeting Solid Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid MalignanciesRecruiting

Solid MalignanciesPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Solid Malignancies

#DrugCompanyPhaseTrials

Dostarlimab

Incyte

Phase 2

1 2

Jakafi

Incyte

Phase 2

1 3

Imfinzi

AstraZeneca

Phase 1

1 4

Imjudo

AstraZeneca

Phase 1

1 5

IM-1021

IImmunome, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Solid Malignancies

NCT06823167

Clinical

Trials by Indication[1]

Solid Malignancies1 trial

A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies

Recruiting·IImmunome, Inc.·Phase 1·NCT06823167·190 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IM-1021. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IM-1021 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IM-1021. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immunome, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: IImmunome, Inc.

IM-1021

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Solid Malignancies1 trial

References

Drug Info

Quick Facts

Related News